11 – 20 of 25
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register–a validation study
(
- Contribution to journal › Article
-
Mark
Clinical effectiveness of golimumab in ulcerative colitis : a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG
(
- Contribution to journal › Article
-
Mark
Predictors of drug survival : A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register
(
- Contribution to journal › Article
-
Mark
Real-world effectiveness of vedolizumab in inflammatory bowel disease : week 52 results from the Swedish prospective multicentre SVEAH study
(
- Contribution to journal › Article
- 2020
-
Mark
Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis : results from a nationwide study in Sweden
(
- Contribution to journal › Article
-
Mark
The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register
(
- Contribution to journal › Article
- 2019
-
Mark
Swedish Inflammatory Bowel Disease Register (SWIBREG) - a nationwide quality register
(
- Contribution to journal › Scientific review
- 2018
-
Mark
Inflammatory bowel disease registries for collection of patient iron parameters in Europe
(
- Contribution to journal › Scientific review
-
Mark
Clinical effectiveness of golimumab in Crohn’s disease : an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
(
- Contribution to journal › Article
- 2017
-
Mark
Long-term effectiveness of vedolizumab in inflammatory bowel disease : a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
(
- Contribution to journal › Article